Introduction
============

CPE-NFα1, a member of the M14 metallocarboxypeptidase family was discovered in 1982 in bovine adrenal medulla and named as enkephalin convertase due to its enzymatic activity in processing enkephalin precursor into its mature form ([@B17]). Since then, CPE-NFα1 has been shown to cleave C-terminal basic amino acids from the intermediates generated by proprotein convertases' action on prohormones, thereby producing bioactive hormones and neuropeptides ([@B18]; [@B17]; [@B15]). In the central nervous system, CPE-NFα1 also functions as a regulated secretory pathway sorting receptor, secretory vesicle transport regulator and mediates synaptic vesicle localization to the active zone for release ([@B3]; [@B23]). Recent studies have indicated that CPE-NFα1 is a new neurotrophic factor functioning extracellularly, independent of its enzymatic activity, in the adult and embryonic central nervous system ([@B23]). Human mutations of CPE-NFα1 have been associated with obesity, diabetes, infertility, learning disabilities, and Alzheimer's disease (AD) ([@B1]; [@B5]). This review presents recent advances concerning the molecular structure, distribution, and multifunctional roles of CPE-NFα1 and its variants in the central nervous system in health and disease.

Molecular Structure and Biosynthesis of CPE-NFα1 and Its Variants
=================================================================

In mammals, WT-CPE-NFα1 gene consists of nine exons and encodes a 476 amino acid polypeptide ([@B25]; [@B3]). Two CPE-NFα1 mRNA transcripts, 2.4 and 1.7 kb in size, respectively, have been identified by Northern Blot analysis and DNA sequencing from human cancer cells. The 2.4 kb CPE-NFα1 transcript encodes a 53 kD WT-CPE/NFα1 and the 1.7 kb transcript encodes an N-terminal truncated 40 kD CPE-NFα1 due to the intra-exonic splicing in exon1 ([@B59]). Both transcripts have also been detected in Northern blot of human hippocampal mRNA extract (Yang, our unpublished data). Three CPE-NFα1 transcripts, a 2.3 kb WT transcript and two CPE-NFα1 mRNA variants, 1.9 and 1.73 kb in size ([Figure 1](#F1){ref-type="fig"}) have been identified in mouse embryonic brain. Unlike in human cancer cells, the two mouse CPE-NFα1 mRNA variants are generated by using alternative transcription start sites, each of them encodes an N-terminal truncated CPE-NFα1 with a molecular weight of 47 and 40 kD, respectively ([@B59]; [@B58]).

![mRNA and protein structure of mouse CPE-NFα1. There are three CPE-NFα1 transcripts: a 2.3 kb CPE-NFα1 mRNA WT transcript and two variants, 1.9 and 1.73 kb transcripts generated by alternative transcription start sites in mouse embryonic brain. CPE-NFα1 mRNA WT transcript produces a 53 kD protein, while the two mouse CPE-NFα1 mRNA variants produce two N-terminal truncated CPE-NFα1 proteins with 47 and 40 kD, respectively. Numbers in the 47 and 40 kD CPE mRNA refer to their relative position in the wt-CPE mRNA.](fnins-13-00243-g001){#F1}

The CPE-NFα1 protein consists of a signal peptide, a catalytic domain, and a C-terminal domain. A 3-D structure model of CPE-NFα1 shows a zinc binding site in the enzymatic domain, a prohormone sorting signal binding site, an amphipathic α-helical transmembrane domain, and a cytoplasmic tail that interacts with microtubule proteins for vesicle transport ([@B3]). Mature CPE-NF α1 has 476-amino acids. It is synthesized as preproCPE-NFα1 that has a 25-amino acid signal peptide located at the N-terminal that directs proCPE-NFα1 to the cisternae of the rough endoplasmic reticulum (ER) where it is removed ([Figure 2](#F2){ref-type="fig"}). The proCPE-NFα1 is then transported to the granules of the regulated secretory pathway through the Golgi complex where 17-amino acids comprising the pro-region are removed ([@B50]). Further processing at Arg455-Lysine 456 ([@B16]) in the secretory granules yields a soluble form of CPE-NFα1 (50 kDa), while the 53 kD unprocessed form is associated with the granule membrane, with some molecules assuming a transmembrane orientation ([@B3]).

![Synthesis of CPE-NFα1. CPE-NFα1 is synthesized as preproCPE-NFα1 which contains a 25-amino acid signal peptide. In the cisternae of rough endoplasmic reticulum, the signal peptide is removed. Then, the 17-amino acid pro peptide is cleaved in the Golgi complex or granules of the regulated secretory pathway. Further processing at Arg455-Lysine 456 produces a soluble form of CPE-NFα1, with the unprocessed form being membrane associated.](fnins-13-00243-g002){#F2}

Distribution of CPE-NFα1 and CPE-NFα1-ΔN
========================================

In mammals, CPE-NFα1 is generally distributed in the endocrine and nervous system, with the highest concentration in the brain ([@B52]). Immunohistochemical studies showed CPE-NFα1 is located in neuropeptide-rich regions of the brain and endocrine system, for example, in the hypothalamus, pituitary, adrenal medulla, paraventricular nucleus, hippocampus, and amygdala ([@B19]; [@B33]). Consistently, CPE-NFα1 mRNA is also found to be highly expressed in these brain regions ([@B2]; [@B34]; [@B61]). The retina and olfactory bulb are also highly enriched in CPE-NFα1 ([@B63]). In the retina, CPE-NFα1 is localized to the photoreceptors and is involved in synaptic transmission to the inner retina ([@B63]). At the cellular level, CPE-NFα1 is mainly distributed in the trans-Golgi network and dense core secretory granules of endocrine cells and peptidergic neurons ([@B3]). CPE-NFα1 exists as two active forms, the soluble and membrane form ([Figure 2](#F2){ref-type="fig"}). The soluble form of CPE-NFα1 functions as an enzyme that cleaves C-terminal basic residues such as arginine and lysine from intermediates derived from neuropeptide precursors or prohormones to produce biologically active peptides or hormones. The membrane form of CPE-NFα1 acts as a sorting receptor at the trans-Golgi network to direct prohormones to the regulated secretory pathway granules, and mediates secretory granule movement ([@B3]). In contrast, the N-terminal truncated (CPE-NFα1-ΔN) forms which lack a signal peptide do not enter the secretory pathway. The 40 kD form of CPE-NFα1-ΔN has been shown to be localized in the cytoplasm and to be able to translocate into the nucleus where it exerts its effects on gene regulation ([@B43]) (see summary in [Table 1](#T1){ref-type="table"}).

###### 

Comparison of CPE-NFα1 WT and CPE-NFα1-ΔN.

                                                                  CPE-NFα1 WT                                     CPE-NFα1-ΔN
  --------------------------------------------------------------- ----------------------------------------------- ---------------------------------------
  Biosynthesis                                                    First transcription start site                  Alternative transcription start sites
  Intracellular location                                          Regulated secretory vesicles                    Cytoplasm and nucleus
  Distribution                                                    Endocrine and CNS. Embryonic and adult brain    Embryonic, not adult brain in mouse
  Soluble and membrane forms                                      Soluble and membrane associated                 Soluble
  Extracellular secretion                                         Secreted from vesicles to extracellular space   Not secreted
  Signal peptide                                                  Yes                                             No
  Structure                                                       --                                              Lacking N-terminal
  Enzymatic activity                                              Yes                                             Weak enzymatic activity
  Intracellular sorting receptor to regulatory secreted pathway   Yes                                             No
  Facilitates vesicle trafficking via cytoplasmic tail            Yes                                             No

Mice and Humans With CPE-NFα1 Mutation Exhibit Neurological Deficits
====================================================================

CPE-NFα1 knockout (KO) mice, in addition to exhibiting endocrinological deficits such as obesity, diabetes, and infertility due to lack of enzyme activity, display a variety of behavioral abnormalities as evidenced by deficits in learning and memory in Morris water maze, object preference, and social transmission of food preference tests ([@B56]). They also display depressive-like behavior ([@B7], [@B5]). CPE^fat/fat^ mice which have a Ser202Pro mutation and lack CPE-NFα1 have a similar phenotype to the knockout mouse and exhibit anxiety-like and depression-like behaviors ([@B45]). Interestingly, a human with a null mutation also demonstrated similar symptoms, such as obesity, diabetes, hypogonadotropic hypogonadism, and impaired intellectual ability ([@B1]). In another study, a human mutation of CPE-NFα1 with three adenosines insertions was identified, this mutation was named QQ-CPE-NFα1. Mice bearing this mutation showed neurodegeneration in the hippocampus and prefrontal cortex, deficits in neurogenesis at the dentate gyrus and hyperphosphorylation of tau ([@B5]). Another human CPE-NFα1 mutation, T980C, which introduces a W235R change in the catalytic domain of CPE-NFα1 caused a loss of enzyme activity, neurotoxic accumulation in the ER, resulting in ER stress and cell death when overexpressed in Neuro 2A cells. This novel single nucleotide polymorphism in the CPE-NFα1 gene found in 12.5% of the AGI_ASP population may confer neurological disorders in humans ([@B8]). These observations suggest that CPE-NFα1 plays an important role in neurological function, and mutation of this gene can lead to cognitive and neurodegenerative disorders.

CPE-NFα1 in Neurodegenerative Disorders and Stress
==================================================

In the cerebral cortex of AD patients, an abnormal accumulation of CPE-NF α1 was detected in dystrophic neurites surrounding amyloid plaques ([@B41]). In an AD animal model of APPswe/PS1dE9 mice, similar pattern of changes were also found. Amyloid plaques were surrounded by aberrant accumulation of CPE-NFα1 and Secretogranin III (SgIII) ([@B41]). Peptidase activity analysis of the postmortem brain from AD patients showed that soluble enzymatic activity of CPE-NFα1 was significantly increased in the Brodmann Area 21 compared with control ([@B53]). In a Cathepsins B and L double knockout mouse model that demonstrated early-onset neurodegeneration and reduction in brain size, the expression of CPE-NFα1 was upregulated by 10-fold ([@B51]). In experimental autoimmune encephalomyelitis (EAE) animal model, CPE-NFα1 has been mapped as a EAE-linked trait loci which is associated to the severity of the disease and shown to be downregulated ([@B21]; [@B37]). These observations suggest that CPE-NFα1 is associated to the pathophysiology of neurodegenerative diseases.

Studies have shown that CPE-NFα1 expression is up-regulated after different types of stress. CPE-NFα1 mRNA and protein were both increased in the rat hippocampal CA1, CA3, and cortex regions 15 min after transient global ischemia followed by 8 h reperfusion ([@B24]). An accumulation of CPE-NFα1 precursor was found in mouse cortex after focal cerebral ischemia *in vivo* and in ischemic cortical neurons *in vitro*. Vice versa, mice lacking CPE-NFα1 were more vulnerable to focal cerebral ischemia ([@B62]). Stress such as cat odor upregulated CPE-NFα1 gene expression in rat amygdala ([@B26]). Mild chronic restraint stress for 7 days up-regulated CPE-NF α1 expression in mouse hippocampal CA3 region ([@B39]). Reduced levels of CPE-NFα1 were found in the offspring of pregnant ewes that experienced aversive interaction with human handling, along with abnormal corticolimbic dendritic spine morphology ([@B10]). Primary cultured hippocampal neurons derived from CPE-NFα1-KO mice tend to die more rapidly than that from wild type (WT) mice ([@B4]). Low-potassium-induced apoptosis in cultured primary cerebellar granule neurons from CPE-NFα1^+/−^ mice are much higher than that from CPE-NFα1^+/+^ mice ([@B27]). Overexpression of CPE-NFα1 in rat primary hippocampal neurons prevented hydrogen peroxide-induced neurotoxicity ([@B56]). All these studies indicate that stress modulates CPE-NFα1 expression in the central nervous system (CNS).

CPE-NFα1 as a Neurotrophic Factor in Neuroprotection and Anti-Depression
========================================================================

CPE-NFα1 plays multiple intracellular roles in the CNS independent of its enzymatic activity. It functions as a regulated secretory pathway sorting receptor for proneuropeptides ([@B9]) and proBDNF ([@B31]), mediates anterograde transport of neuropeptide and BDNF vesicles to the plasma membrane via cytoplasmic tail interaction with dynactin/dynein ([@B40]), and localizes synaptic vesicles to the actin-rich pre-active zone in hypothalamic neurons through actin binding protein γ-adducin ([@B32]). While the mechanisms underlying these cell biological actions of CPE-NFα1 are well understood, those governing the neuroprotective effects of CPE-NFα1 during stress are just emerging. In 2013, a study showed that CPE-NFα1 secreted from hippocampal neurons, acts as a neuroprotective factor extracellularly, independent of its enzymatic activity ([@B4]). Secreted rat WT CPE-NFα1 and CPE-NFα1-E300Q (mutant form with no enzymatic activity) ([@B42]) in medium from transduced cultured primary rat hippocampal neurons protected them from cell death induced by H~2~O~2~-mediated oxidative stress and glutamate excitotoxicity. Results from experiments with recombinant WT CPE-NFα1 or CPE-NFα1-E342Q (mouse homolog of E300Q) demonstrated similar effects. In addition, hippocampal neurons from CPE-NFα1-KO mice at embryonic day 17 (E17) in culture exhibited higher death rate than WT E17 neurons, and this was reversed by treatment with recombinant WT CPE-NFα1 ([@B4]). Studies on the mechanism underlying the neuroprotective action of CPE-NFα1 using rat primary hippocampal neurons in culture revealed that when these cells were stressed with H~2~O~2~, it activated the ERK and AKT signaling pathways, presumably by binding to a cognate receptor, which then up-regulated expression of Bcl2, a pro-survival mitochondrial protein, and down-regulated expression of Caspase 3 to mediate neuroprotection ([@B4]) (see [Figure 3](#F3){ref-type="fig"}).

![The multiple functions of CPE-NFα1 in the central nervous system (CNS). CPE-NFα1 plays multiple functions in the CNS independent of its enzymatic activity. Short term restraint or weaning stress increases CPE-NFα1 which binds to a cognate receptor and upregulates ERK1/2 and Bcl2, and decreases Bax and cytochrome c-induced activation of caspase 3 and apoptosis. CPE-NFα1 also increases FGF2 that activates AKT and Bcl2 signaling and increases hippocampal neurogenesis and produces antidepressive-like effect. CPE-NFα1 can also bind to Frizzled receptor -- Wnt3a complex, enters the endosome that contains Wnt signaling factors and subsequently impairs the formation of signalosome. This results in β-catenin being degraded, rather than translocation into the nucleus and binds to T-cell factor transcription factor (TCF) to activate expression of Wnt target genes. ![](fnins-13-00243-i001.jpg)Signalosome ![](fnins-13-00243-i002.jpg)Wnt ![](fnins-13-00243-i003.jpg)Fz ![](fnins-13-00243-i004.jpg)APC ![](fnins-13-00243-i005.jpg)GSK-3β ![](fnins-13-00243-i006.jpg)Axin.](fnins-13-00243-g003){#F3}

In an *in vivo* mouse model, complete degeneration of hippocampal CA3 region was observed in CPE-NFα1-KO mice at 4-weeks of age after weaning stress which included maternal separation, ear tagging, and tail snipping at 3 weeks of age ([@B56]). CPE-NFα1-KO mice that were not subjected to the weaning process at 3 weeks of age showed no degeneration of the CA3 region examined at week 4, indicating that this neurodegeneration was not due to a neurodevelopmental defect. Treatment with oral carbamazepine at 50 mg/kg daily for 2 weeks beginning at 2 weeks of age with the weaning process at 3 weeks of age, revealed no degeneration of the CA3 region when examined at 4 weeks of age ([@B55]). These observations suggested that the CA3 pyramidal neurons underwent apoptosis due to glutamate excitotoxicity during the social and physical stress following the weaning protocol. In contrast, WT-mice, did not show any degeneration of the CA3 region after weaning stress. In another mouse model, adult CPE^fat/fat^ mice lacking CPE-NFα1, also showed degeneration of the CA3 region (Zhou, personal communication). These findings together with the *in vitro* studies ([@B4]) support the hypothesis that CPE-NFα1 acts as a neurotrophic factor to protect the pyramidal neurons in the CA3 region in the hippocampus from stress-induced degeneration. Since BDNF is expressed in CPE-NFα1-KO mice ([@B57]), yet they showed neurodegeneration after weaning, indicates that BDNF could not protect the CA3 neurons in lieu of CPE-NFα1. Further demonstration that CPE-NFα1 is a neuroprotective factor *in vivo* during stress came from studies showing that chronic restraint stress of mice for 1 h/day for 7 days resulted in an increase in CPE-NFα1 mRNA and protein expression in the hippocampus, with no evidence of neurodegeneration despite increased circulating corticosterone levels under this stress paradigm ([@B39]). This up-regulation in expression of CPE-NFα1 concurrs with *in vitro* evidence showing that the CPE-NFα1 promoter has a glucocorticoid binding domain and that dexamethasone up-regulated the expression of CPE-NFα1 ([@B39]). These mice also showed an increase in phosphorylation of Akt and Bcl2 expression; however, Bax, a pro-apoptotic mitochondria protein was decreased in the hippocampus ([@B39]). In contrast, CPE-NFα1-KO mice subjected to the same stress paradigm showed no change in Akt phosphorylation, a decrease in expression of Bcl2 protein and an increase in Bax protein in the hippocampus compared to WT mice ([@B39]). *In vitro* and *in vivo* evidence taken together indicate that during emotional and physical stress, secretion of glucocorticoid increases CPE-NFα1 expression at the transcriptional and translational level in the hippocampus which in turn leads to neuroprotection of the CA1-3 neurons by acting extracellularly as a trophic factor to activate Erk or Akt signaling and increase Bcl2 pro-survival protein expression (see [Figure 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). CPE-NFα1 also up-regulates the expression of FGF2 ([@B7]), which has been shown to mediate protection against amyloid beta- or glutamate-induced neurotoxicity in hippocampal or cortical neurons via the Akt-Bcl2 signaling pathway ([@B43]; [@B6]; [Figure 3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}).

![Neuroprotective effect of CPE-NFα1. Short term stress activates the hypothalamic-pituitary-adrenal axis which then increases ACTH and glucocorticoid secretion. The glucocorticoids upregulate CPE-NFα1 expression via glucocorticoid regulatory elements (GRE) on the promoter. CPE-NFα1 is secreted and possibly activates its cognate receptor which then produces antidepressant-like effects via increasing FGF2 expression and neurogenesis in the hippocampus. Additionally, CPE-NFα1 protects against neurodegeneration through upregulating Bcl2, a mitochondrial pro-survival protein, by inhibiting caspase 3-mediated apoptosis.](fnins-13-00243-g004){#F4}

![Gene regulation function of CPE-NFα1-ΔN in mouse embryonic neurons. CPE-NFα1-ΔN increases expression of FGF2, IGFBP2, EFNA1, and DAP1 in mouse embryonic cortical and hippocampal neurons. IGFBP2 promotes neuronal proliferation while FGF2 inhibits oxidative stress or glutamate-induced excitotoxicity. FGF2 binds its receptor and induces neuroprotective effects via activating the AKT and Bcl2 signaling cascade. CPE-NFα1-ΔN expressed in hippocampal neurons translocates into the nucleus and upregulates β-catenin expression. β-catenin then enters the nucleus and binds to T-cell factor (TCF) transcription factor to promote expression of Wnt target genes.](fnins-13-00243-g005){#F5}

Behavioral analysis revealed that the CPE-NFα1-KO and the Cpe^fat/fat^ mice exhibited depressive-like behavior as evidenced by increased immobility time in the forced-swimming test ([@B45]; [@B7]). CPE-NFα1-KO mice showed decreased levels of FGF2 ([@B7]), a protein demonstrated to be decreased in post mortem brains of patients with major depressive disorder ([@B12]). In addition, after long-term chronic restraint stress, mice showed depressive-like behavior, and reduced CPE-NFα1, FGF2 and doublecortin, a marker for neuroblasts in their hippocampus. Interestingly, injection of 5 ng/g recombinant FGF2 into CPE-NFα1-KO mouse for 30 consecutive days completely reversed the decreased number of doublecortin positive neurons in the subgranular zone of hippocampus and depressive-like behaviors as evidenced by decreased immobility time in the forced-swim test ([@B7]). *In vitro* studies showed that incubation of rat cultured hippocampal neurons with CPE-NFα1 enhanced FGF2 mRNA and protein expression which was inhibited by the Sp1 inhibitor mithramycin A, a transcription inhibitor actinomycin, and ERK inhibitor U0126, suggesting that CPE-NFα1 can upregulate FGF2 via ERK-Sp1 signaling cascade ([@B7]). Thus, CPE-NFα1 may act as an anti-depressant through up-regulating FGF2 expression in the hippocampus.

Role of CPE-NFα1 and CPE-NFα1-ΔN Variants in Neurodevelopment
=============================================================

In mice and rats, CPE-NFα1 mRNA is expressed during embryogenesis as early as E5.5 mainly in the developing nervous system ([@B61]; [@B48]). In mice, the expression of CPE-NFα1-WT and the two CPE-NFα1-ΔN transcripts were detected in E8.5 embryonic brain and their expression peaked at embryonic day (E)10.5, then decreased from E12.5 to E16.5, and increased again at postnatal day 1 (P1). Interestingly, none of the CPE-NFα1-ΔN mRNAs were found in adult mouse hippocampus or other organs such as liver, heart or lung, suggesting their critical role during embryonic neurodevelopment ([@B58]). Studies of dendritic arborization in pyramidal layer V of cerebral cortex and hippocampal CA1 region in 14-week-old CPE-NFα1-KO mice revealed abnormal dendritic pruning and increased number of non-functional D-type spines ([@B54]), suggesting a role of CPE-NFα1 in modeling the cytoarchitecture of the brain during development. Indeed, CPE-NFα1 has been shown to regulate NGF-induced neurite outgrowth via interacting with Wnt-3a and Wnt-5a in PC12 cells and mouse primary cortical neurons ([@B47]). CPE-NFα1 is highly expressed in neural stem cells ([@B28]) and has been shown to inhibit embryonic neural stem cell proliferation by downregulating Wnt signaling pathway and β-catenin ([@B48]). Studies have revealed that CPE-NFα1 forms a complex with Wnt3a ligand and Frizzled receptor to inhibit the Wnt3a signaling cascade ([Figure 3](#F3){ref-type="fig"}; [@B49]). Moreover, exogenous application of CPE-NFα1 and a non-enzymatic form of CPE-NF α1(E300Q) induced differentiation of E14.5 cortical neural stem cells into astrocytes via activating the ERK1/2-Sox9 signaling pathway to enhance glial fibrillary acidic protein (GFAP) expression ([@B48]). This corroborates the 49% decrease in astrocyte numbers observed in the neocortex of mouse neonates *in vivo* at postnatal day 1 (P1). In another study, electroporation of CPE-NFα1 shRNA into E14.5 mouse embryos significantly decreased migration of neurons to cortex plate at E17.5, possibly due to the failure of transition from multipolar neurons into a bipolar morphology in the intermediate zone ([@B30]). Neuronal migration seems to depend on the function of the CPE-NFα1 cytoplasmic tail which can interact with dynactin, an adaptor protein that interacts with microtubules. Furthermore, this study also showed that CPE-NFα1 regulates dendrite morphology *in vivo* and in rat primary cultured hippocampal neurons ([@B30]).

While CPE-NFα1 acts extracellularly as an embryonic stem cell differentiation and anti-proliferation factor, studies have indicated that CPE-NFα1-ΔN could serve as a master regulator of genes involved in neurodevelopment ([Figure 5](#F5){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). CPE-NFα1-ΔN (40 kD variant), but not CPE-NFα1 (Xiao, our unpublished data) was found to significantly up-regulate expression of four genes, fibroblast growth factor 2 (FGF2) ([@B43]), insulin-like growth factor binding protein2 (IGFBP2), death associated protein (DAP1), and EphrinA1 in HT22, a hippocampal cell line and in primary mouse cortical neurons ([@B58]). These three genes are known to mediate neuronal proliferation, cell death and neuronal migration, respectively ([@B38]; [@B11]; [@B14]; [@B29]; [@B35]; [@B36]; [@B46]; [@B60]). Overexpressing of CPE-NF α1-ΔN in HT22 cells promoted proliferation, but was inhibited by IGFBP2 siRNA, suggesting CPE-NFα1-ΔN regulates embryonic neuronal proliferation through increasing IGFBP2. In addition, CPE-NFα1-ΔN-induced FGF2 expression has a neuroprotective role against glutamate and H~2~O~2~ neurotoxicity in rat embryonic cortical neurons ([@B43]). Since FGF2 is also known to play a role in neuronal proliferation and neurogenesis in the developing mouse cortex, CPE-NFα1-ΔN may also regulate these events in the embryonic brain ([@B44]). Moreover, CPE-NFα1-ΔN has been shown to up-regulate the expression of β-catenin in the Wnt pathway in HEK-293 cells ([@B49]) and osteosarcoma cell lines, which promoted migration of these cells ([@B13]). We have shown that neuroprotection by CPE-NFα1-ΔN against glutamate excitotoxicity may also involve β-catenin and Wnt pathway. Glutamate treatment resulted in a decrease in β-catenin level and poor cell viability compared to untreated control embryonic rat cortical neurons. However, in CPE-NFα1-ΔN-transduced neurons treated with glutamate, this decrease in β-catenin did not occur and the cell viability was similar to control. Treatment of cortical neurons with XAV939 which stimulates degradation of β-catenin ([@B20]) showed that in the presence of XAV939, the neuroprotective effect of CPE-NFα1-ΔN against glutamate neurotoxicity was abolished. This suggests that the activation of the Wnt/β-catenin pathway may also contribute to the neuroprotective mechanism of CPE-NFα1-ΔN in embryonic neurons (Qin et al., our unpublished data). Additionally, β-catenin has been reported to mediate neuronal proliferation and differentiation of stem cells ([@B22]). Thus, CPE-NFα1-ΔN may also regulate these processes during development via the Wnt signaling pathway.

###### 

Neuroprotective and neurodevelopmental functions of CPE-NFα1 WT and CPE-NFα1-ΔN.

                        Function                                                                                                              Reference
  --------------------- --------------------------------------------------------------------------------------------------------------------- ----------------
  CPE-NFα1 WT           Regulates NGF-induced neurite outgrowth                                                                               [@B47]
                        Inhibits neuronal stem cell proliferation                                                                             [@B48]
                        Induces differentiation of neural stem cells into astrocytes                                                          [@B48]
                        Regulates cortical neuron migration and dendrite arborization                                                         [@B30]
                        Protects primary cultured rat hippocampal neurons from H~2~O~2~-induced oxidative stress                              [@B4]
                        CA3 completely degenerated after weaning, ear tag and tail clipping at 3-week of age and prevented by carbamazepine   [@B56], [@B55]
                        Upregulates FGF2 and produces antidepressant-like effects                                                             [@B7]
  CPE-NFα1-ΔN (40 kD)   Protects primary rat embryonic cortical neurons from glutamate and H~2~O~2~-induced apoptosis via FGF2                [@B43]
                        Increases proliferation via upregulating IGFBP2                                                                       [@B58]

Conclusion
==========

CPE-NFα1 is a multifunction protein ([Table 2](#T2){ref-type="table"}). In addition to being a prohormone and proneuropeptide processing enzyme, it is a sorting receptor and vesicle transport mediator. Recent studies have shown that it also plays a fundamental role in neurodevelopment, neurodegeneration, and cognitive functions. Null mutation of CPE-NFα1 in animal models and a human both produced similar deficits, including obesity, diabetes, and compromised cognitive function and memory. In addition, abnormal accumulation in the ER of a human mutant of CPE-NFα1 from an AD patient was found which caused neurotoxicity, neurodegeneration, and cognitive impairment in an animal model. *In vitro* studies using primary neurons in culture indicate that CPE-NFα1 acts extracellularly as a trophic factor, independent of enzymatic activity to mediate neuroprotection via activating several pro-survival signaling cascades such as upregulating Bcl2 and FGF2 signaling. Studies to demonstrate the neurotrophic effect *in vivo* will be necessary using transgenic mouse models to further support this hypothesis. Additionally, identifying a membrane receptor for CPE-NFα1 will be required to substantiate a receptor-mediated mechanism for activating signaling pathways for neuroprotection and stem cell differentiation. Furthermore, CPE-NFα1 and its derived peptides can be developed as potential therapeutic agents to treat neurodegenerative diseases. The 40 kD CPE-NFα1-ΔN variant has been shown to activate genes involved in neurodevelopment ([Table 2](#T2){ref-type="table"}). Further studies will be required to determine the precise molecular mechanism underlying CPE-NFα1-ΔN's role in activating such genes during embryonic development.
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